HSPB1 and breast carcinoma: The results indicated that HSPB1 overexpression decreased erastin-induced growth inhibition and ROS production in breast cancer cells, and Fer-1 treatment showed a synergistic effect with HSPB1 overexpression (Supplementary Fig. S5D, E).